PRAX News and Press, Praxis Precision Medicines Inc. From 08/02/21

CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance,...

Praxis Precision Medicines (PRAX) announces the appointment of Tim Kelly as the company's chief financial officer, effective immediately.Kelly joins Praxis from Foundation Medicine, where he served as chief financial officer and head of corporate management.He has more than 20 years...

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today...

The following slide deck was published by Praxis Precision Medicines, Inc. in conjunction with this event. For further details see: Praxis Precision Medicines (PRAX) Investor Presentation - Slideshow

CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, ...

Praxis Precision Medicines (PRAX) has priced its public offering of 5M common shares at $18.25/share, for expected gross proceeds of ~$91.25M.Underwriters' over-allotment is an additional 750K shares. Net proceeds will be used for advancement of pipeline candidates and other programs, for wor...

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today...

Gainers: Curis (CRIS) +53%.Second Sight Medical Products (EYES) +44%.Summit Wireless Technologies (WISA) +39%.Barnwell Industries (BRN) +36%.Autolus Therapeutics (AUTL) +31%.Ra Medical Systems (RMED) +29%.ShotSpotter (SSTI) +23%.Ideal Power (IPWR) +22%.Minerva Neurosciences (NE...

Gainers: Ra Medical Systems (RMED) +67%, Nemaura Medical (NMRD) +23%, Lucira Health (LHDX) +21%, Minerva Neurosciences (NERV) +20%, Harrow Health (HROW) +19%.Losers: InflaRx (IFRX) -15%, Praxis Precision Medicines (PRAX) -14%, Lianlu...

Praxis Precision Medicines (PRAX) announces that it has commenced an underwritten public offering of 4M shares.Intends to grant the underwriters a 30-day option to purchase up to an additional 15% of shares.Praxis intends to use net proceeds, together with existing cash, for the advancem...